Alligator Bioscience

    OverviewSuggest Edit

    Alligator Bioscience develops antibody-based pharmaceuticals for cancer treatment. The Company is specialized in the development of tumor-targeted immunotherapies, particularly agonistic mono- and bispecific antibodies, and is engaged in the early stages of drug development, from the idea stage to clinical phase II trials.

    TypePublic
    Founded2001
    HQLund, SE
    Websitealligatorbioscience.se

    Latest Updates

    Employees (est.) (Feb 2019)53(+9%)

    Key People/Management at Alligator Bioscience

    Peter Benson

    Peter Benson

    Chairman
    Carl Borrebaeck

    Carl Borrebaeck

    Board Member
    Ulrika Danielsson

    Ulrika Danielsson

    Board Member
    Anders Ekblom

    Anders Ekblom

    Board Member
    Jonas Sjögren

    Jonas Sjögren

    Board Member
    Laura von Schantz

    Laura von Schantz

    Board Member
    Show more

    Alligator Bioscience Office Locations

    Alligator Bioscience has an office in Lund
    Lund, SE (HQ)
    2 Scheelevägen
    Show all (1)
    Report incorrect company information

    Alligator Bioscience Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    Alligator Bioscience News and Updates

    Alligator Bioscience AB Year-end Report 2018

    STOCKHOLM, Feb. 14, 2019 /PRNewswire/ -- Significant events October-December The Swedish MPA (Medical Products Agency) approved start of Phase I clinical trial of ATOR-1015. New preclinical data for ATOR-1017 and ALG.APV-527 presented at the Annual Meeting of the Society for Immunotherapy ...

    Alligator Bioscience Publishes Clinical Phase I Data for ADC-1013 in the International Journal of Cancer

    LUND, Sweden, Jan. 29, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), announces the publication of the results from a clinical phase I first-in-human study of the CD40 agonistic antibody ADC-1013 (JNJ-64457107). The top line data from this study was presented at the...

    Alligator Bioscience Launches RUBY™, a Novel Concept in Bispecific Antibody Formats

    LUND, Sweden, Jan. 7, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), announces the launch of a novel concept in bispecific antibody formats, RUBY™. The RUBY concept gives Alligator competitive abilities to generate therapeutic antibodies that are both efficient and...

    Alligator Bioscience Starts Clinical Phase I Study With ATOR-1015

    LUND, Sweden, Dec. 11, 2018 /PRNewswire/ -- Alligator Bioscience AB (Nasdaq Stockholm: ATORX) today announces that regulatory approvals have been obtained for the first clinical study of ATOR-1015 and patient recruitment can now be initiated. ATOR-1015 is a wholly-owned drug candidate...

    Frontier - A Magazine about Alligator Bioscience and Immuno-oncology

    STOCKHOLM, Dec 10, 2018 /PRNewswire/ -- The science behind the Nobel Prizes in Medicine and Chemistry is the core in Alligator's research and development Read the full magazine through the link below. About Alligator Bioscience Alligator Bioscience AB is a clinical-stage biotechnology...

    Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting

    LUND, Sweden and SEATTLE, Nov. 9, 2018 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, and Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on...
    Show more
    Report incorrect company information

    Alligator Bioscience Blogs

    Alligator Bioscience: New preclinical data demonstrate strong anti-tumor effects for the 4-1BB antibody ATOR-1017

    Lund, Sweden, March 18, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that they will present preclinical data for the drug candidate ATOR-1017 at the 4th Annual Immuno-oncology Summit Europe, to be held in London on March 18-22, 2019. ATOR-1017 is a monoclonal antibody in dev…

    Alligator Bioscience to Host Conference Call to Provide Year-end Report 2018 Business Update

    Alligator Bioscience (Nasdaq Stockholm: ATORX) – On 14 February 2019, at 08:00 a.m. CET, Alligator Bioscience will publish its report for the year ended 31 December 2018. All interested parties are invited to participate in a telephone conference, which will include a presentation of the Year-end Re…

    Alligator Bioscience publishes clinical phase I data for ADC-1013 in the International Journal of Cancer

    First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies Inlägget Alligator Bioscience publishes clinical phase I data for ADC-1013 in the International Journal of Cancer dök först upp på Alligator Bioscience.

    Alligator Bioscience launches RUBY™, a novel concept in bispecific antibody formats

    Priority filling submitted RUBY™ bispecific concept has been developed to achieve an outstanding stability, manufacturability and shorter development timelines Inlägget Alligator Bioscience launches RUBY™, a novel concept in bispecific antibody formats dök först upp på Alligator Bioscience.

    Frontier – A Magazine about Alligator Bioscience and Immuno-oncology

    The science behind the Nobel Prizes in Medicine and Chemistry is the core in Alligator’s research and development Read the full magazine here. About Alligator Bioscience Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alliga…

    Alligator Bioscience starts clinical phase I study with ATOR-1015

    A first-in-class bispecific CTLA-4 antibody Inlägget Alligator Bioscience starts clinical phase I study with ATOR-1015 dök först upp på Alligator Bioscience.
    Show more

    Alligator Bioscience Frequently Asked Questions

    • When was Alligator Bioscience founded?

      Alligator Bioscience was founded in 2001.

    • Who are Alligator Bioscience key executives?

      Alligator Bioscience 's key executives are Peter Benson, Carl Borrebaeck and Ulrika Danielsson.

    • How many employees does Alligator Bioscience have?

      Alligator Bioscience has 53 employees.

    • Who are Alligator Bioscience competitors?

      Competitors of Alligator Bioscience include FLX Bio, MolMed and Innocare.

    • Where is Alligator Bioscience headquarters?

      Alligator Bioscience headquarters is located at 2 Scheelevägen, Lund.

    • Where are Alligator Bioscience offices?

      Alligator Bioscience has an office in Lund.

    • How many offices does Alligator Bioscience have?

      Alligator Bioscience has 1 office.